BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35951084)

  • 1. Safety of [
    Ruigrok EAM; Verhoeven M; Konijnenberg MW; de Blois E; de Ridder CMA; Stuurman DC; Bertarione L; Rolfo K; de Jong M; Dalm SU
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4440-4451. PubMed ID: 35951084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Balance Between the Therapeutic Efficacy and Safety of [
    Verhoeven M; Haeck J; de Blois E; Orlandi F; Barbato D; Tedesco M; Konijnenberg M; Dalm SU
    Mol Imaging Biol; 2024 Feb; 26(1):114-123. PubMed ID: 37640941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.
    Damiana TST; Paraïso P; de Ridder C; Stuurman D; Seimbille Y; Dalm SU
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3851-3861. PubMed ID: 37584725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor.
    Montemagno C; Raes F; Ahmadi M; Bacot S; Debiossat M; Leenhardt J; Boutonnat J; Orlandi F; Barbato D; Tedesco M; Ghezzi C; Perret P; Broisat A
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
    Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution, Pharmacokinetics, and Dosimetry of
    Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
    J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.
    Verhoeven M; Ruigrok EAM; van Leenders GJLH; van den Brink L; Balcioglu HE; van Weerden WM; Dalm SU
    Front Oncol; 2023; 13():1199432. PubMed ID: 37719014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 13. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
    Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
    Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
    J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor-Positive Prostate Cancer.
    Bratanovic IJ; Zhang C; Zhang Z; Kuo HT; Colpo N; Zeisler J; Merkens H; Uribe C; Lin KS; Bénard F
    J Nucl Med; 2022 Mar; 63(3):424-430. PubMed ID: 34301778
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
    J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
    Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
    Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.